Bristol-Myers Squibb names Fouad Namouni as head of oncology development

Fouad Namouni has been appointed oncology development head at US pharma major Bristol-Myers Squibb (NYSE: BMY), effective July 25, 2016.

Dr Namouni will be responsible for leading the execution of a comprehensive development strategy for the company’s robust oncology pipeline from the early development stage through commercialization. He will continue to report to Francis Cuss, executive vice president, chief scientific officer, and remain a member of the R&D Leadership Team. Dr Namouni, who joined Bristol-Myers in 1999, most recently served as head of medical, leading the worldwide medical organization and prior to that, was the development lead for Yervoy (ipilimumab) and Opdivo (nivolumab).

“Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs throughout his career at Bristol-Myers Squibb,” said Dr Cuss, adding: “As a trained pediatric oncologist, Fouad brings to this role exceptional clinical experience and an unwavering commitment to patients. I am confident that our oncology development programs will continue to thrive under his leadership.”